6-Jan-2025
FDA issues first draft guidance on use of AI in drug, medical device development
Seeking Alpha News (Mon, 6-Jan 12:52 PM ET)
Healthcare sector's 2024 gainers and losers: Intuitive Surgical, Boston Scientific tops chart
Seeking Alpha News (Mon, 6-Jan 10:00 AM ET)
Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner
PRNewswire (Mon, 6-Jan 9:00 AM ET)
Here are J. P. Morgan’s top MedTech picks for 2025
Seeking Alpha News (Sat, 4-Jan 3:36 PM ET)
Bullish On BSX? You Might Want To Consider This Credit Put Spread Expiring in 10 Days
Market Chameleon (Fri, 3-Jan 5:20 AM ET)
PRNewswire (Thu, 2-Jan 8:00 AM ET)
Boston Scientific CMO Discuss Solutions for Health Inequality on Today's Marketplace
PRNewswire (Wed, 11-Dec 8:08 AM ET)
Boston Scientific Announces Agreement to Acquire Intera Oncology Inc.
PRNewswire (Mon, 25-Nov 7:00 AM ET)
PRNewswire (Sat, 16-Nov 3:07 PM ET)
Boston Scientific Closes Acquisition of Axonics, Inc.
PRNewswire (Fri, 15-Nov 8:43 AM ET)
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Boston Scientific trades on the NYSE stock market under the symbol BSX.
As of January 6, 2025, BSX stock price climbed to $91.29 with 4,487,037 million shares trading.
BSX has a beta of 0.71, meaning it tends to be less sensitive to market movements. BSX has a correlation of 0.33 to the broad based SPY ETF.
BSX has a market cap of $134.44 billion. This is considered a Large Cap stock.
Last quarter Boston Scientific reported $4 billion in Revenue and $.63 earnings per share. This beat revenue expectation by $169 million and exceeded earnings estimates by $.04.
In the last 3 years, BSX traded as high as $91.93 and as low as $34.98.
The top ETF exchange traded funds that BSX belongs to (by Net Assets): VTI, VOO, SPY, IVV, VUG.
BSX has outperformed the market in the last year with a price return of +58.5% while the SPY ETF gained +28.5%. BSX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.9% and +2.6%, respectively, while the SPY returned +5.2% and +0.7%, respectively.
BSX support price is $89.66 and resistance is $91.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BSX shares will trade within this expected range on the day.